1. Home
  2. TRIN vs OCS Comparison

TRIN vs OCS Comparison

Compare TRIN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRIN

Trinity Capital Inc.

HOLD

Current Price

$16.84

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Oculis Holding AG Ordinary shares

OCS

Oculis Holding AG Ordinary shares

HOLD

Current Price

$11.09

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRIN
OCS
Founded
2007
2003
Country
United States
Switzerland
Employees
109
60
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TRIN
OCS
Price
$16.84
$11.09
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$16.00
$42.00
AVG Volume (30 Days)
941.6K
1.1M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
12.61%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.41
$466.06
Revenue Next Year
$10.00
$479.73
P/E Ratio
$7.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.76
$10.52
52 Week High
$17.38
$34.48

Technical Indicators

Market Signals
Indicator
TRIN
OCS
Relative Strength Index (RSI) 50.40 23.83
Support Level $16.56 $10.52
Resistance Level $17.31 $21.50
Average True Range (ATR) 0.29 1.05
MACD -0.05 -0.08
Stochastic Oscillator 18.80 10.40

Price Performance

Historical Comparison
TRIN
OCS

About TRIN Trinity Capital Inc.

Trinity Capital Inc is an internally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, capital appreciation through investments across five distinct vertical markets. The company is focused on achieving its investment objective by operating as a specialty lending company that provides debt, including loans, equipment financings, and asset-based lending, to growth-oriented companies, including institutional investor-backed companies. Its investment portfolio mainly comprises private companies that have begun to have success selling their products to the market and need additional capital to expand their operations and sales.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Share on Social Networks: